

Theodore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9832094/publications.pdf>

Version: 2024-02-01

56
papers

3,888
citations

218677

26
h-index

161849

54
g-index

56
all docs

56
docs citations

56
times ranked

2941
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria. <i>Clinics in Chest Medicine</i> , 2015, 36, 13-34.	2.1	665
2	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	5.8	367
3	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	5.8	357
4	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	6.7	336
5	Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. <i>Thorax</i> , 2007, 62, 661-666.	5.6	282
6	Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1559-1569.	5.6	206
7	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	6.7	159
8	Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015. <i>Annals of the American Thoracic Society</i> , 2020, 17, 178-185.	3.2	159
9	Hypersensitivity Pneumonitis Reaction to <i>Mycobacterium avium</i> in Household Water. <i>Chest</i> , 2005, 127, 664-671.	0.8	151
10	Increased risk of mycobacterial infections associated with anti-rheumatic medications. <i>Thorax</i> , 2015, 70, 677-682.	5.6	134
11	The risk of mycobacterial infections associated with inhaled corticosteroid use. <i>European Respiratory Journal</i> , 2017, 50, 1700037.	6.7	122
12	Pulmonary Nontuberculous Mycobacteria-Associated Deaths, Ontario, Canada, 2001-2013. <i>Emerging Infectious Diseases</i> , 2017, 23, 468-476.	4.3	64
13	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. <i>Annals of the American Thoracic Society</i> , 2016, 13, S379-S384.	3.2	58
14	Risk of Mycobacterial Infections Associated With Rheumatoid Arthritis in Ontario, Canada. <i>Chest</i> , 2014, 146, 563-572.	0.8	55
15	Procedure volume and mortality after surgical lung biopsy in interstitial lung disease. <i>European Respiratory Journal</i> , 2019, 53, 1801164.	6.7	54
16	Aging, COPD, and Other Risk Factors Do Not Explain the Increased Prevalence of Pulmonary <i>Mycobacterium avium</i> Complex in Ontario. <i>Chest</i> , 2012, 141, 190-197.	0.8	53
17	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. <i>Lancet Infectious Diseases</i> , 2022, 22, e178-e190.	9.1	51
18	Nontuberculous Mycobacterial Lung Infections in Ontario, Canada: Clinical and Microbiological Characteristics. <i>Lung</i> , 2010, 188, 289-299.	3.3	49

#	ARTICLE	IF	CITATIONS
19	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	1.6	45
20	Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. <i>Respiratory Medicine</i> , 2018, 145, 80-88.	2.9	33
21	Mortality Prediction in Pulmonary Mycobacterium Kansasii Infection and Human Immunodeficiency Virus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 793-798.	5.6	32
22	Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease. <i>European Respiratory Journal</i> , 2016, 48, 928-931.	6.7	32
23	A Systematic Review of the Clinical Significance of Pulmonary Mycobacterium kansasii Isolates in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 883-889.	2.1	31
24	Obliterative Bronchiolitis Complicating Bone Marrow Transplantation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2003, 24, 531-542.	2.1	30
25	Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 366-372.	2.0	30
26	Amikacin Liposome Inhalation Suspension for <i>Mycobacterium avium</i> Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1147-1157.	3.2	29
27	Comparison of the Spectrum of Radiologic and Clinical Manifestations of Pulmonary Disease Caused by <i>Mycobacterium avium</i> Complex and <i>Mycobacterium xenopus</i> . <i>Canadian Association of Radiologists Journal</i> , 2014, 65, 207-213.	2.0	27
28	Tuberculosis Among Tibetan Refugee Claimants in Toronto. <i>Chest</i> , 2003, 124, 915-921.	0.8	24
29	Health-related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review. <i>Respirology</i> , 2016, 21, 1015-1025.	2.3	23
30	Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. <i>American Journal of Medicine</i> , 2004, 116, 385-393.	1.5	22
31	Inpatient Care of Community-Acquired Pneumonia: The Effect of Antimicrobial Guidelines on Clinical Outcomes and Drug Costs in Canadian Teaching Hospitals. <i>Canadian Respiratory Journal</i> , 2004, 11, 131-137.	1.6	17
32	Variable agreement among experts regarding <i>Mycobacterium avium</i> complex lung disease. <i>Respirology</i> , 2015, 20, 348-351.	2.3	17
33	Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1120-1128.	3.2	17
34	Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada. <i>BMC Pharmacology & Toxicology</i> , 2019, 20, 37.	2.4	16
35	Opinions Differ by Expertise in <i>Mycobacterium avium</i> Complex Disease. <i>Annals of the American Thoracic Society</i> , 2014, 11, 17-22.	3.2	15
36	Health Care Utilization and Expenditures Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 964-974.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. <i>European Respiratory Journal</i> , 2018, 51, 1702330.	6.7	11
38	Chest computed tomography predicts microbiological burden and symptoms in pulmonary <i>Mycobacterium xenopi</i> . <i>Respirology</i> , 2013, 18, 92-101.	2.3	10
39	Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2014, 41, 2326-2328.	2.0	10
40	Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease. <i>Respirology</i> , 2015, 20, 987-993.	2.3	9
41	Clinical outcomes in <i>Mycobacterium xenopi</i> versus <i>Mycobacterium avium</i> complex pulmonary disease: A retrospective matched cohort study. <i>Respiratory Medicine</i> , 2020, 167, 105967.	2.9	9
42	Non-tuberculous mycobacterial infections at San Francisco General Hospital. <i>Clinical Respiratory Journal</i> , 2015, 9, 436-442.	1.6	8
43	Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease. <i>Journal of Medical Economics</i> , 2019, 22, 1126-1133.	2.1	8
44	Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis. <i>American Journal of Audiology</i> , 2021, 30, 800-809.	1.2	8
45	<i>Mycobacterium xenopi</i> Genotype Associated with Clinical Phenotype in Lung Disease. <i>Lung</i> , 2018, 196, 213-217.	3.3	7
46	Radiologic types of <i>Mycobacterium xenopi</i> pulmonary disease: different patients with similar short-term outcomes. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 373-381.	2.9	6
47	Clinical efficacy and safety of fluoroquinolone containing regimens in patients with <i>Mycobacterium avium</i> complex pulmonary disease. <i>European Respiratory Journal</i> , 2020, 55, 1901240.	6.7	6
48	Multilocus Sequence Typing of <i>Mycobacterium xenopi</i> . <i>Journal of Clinical Microbiology</i> , 2014, 52, 3973-3977.	3.9	5
49	Outcomes of a Peri- and Postoperative Management Protocol for Non-TB Mycobacteria in Lung Transplant Recipients. <i>Chest</i> , 2020, 158, 523-528.	0.8	4
50	Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. <i>Chest</i> , 2021, 160, 2042-2050.	0.8	3
51	Nontuberculous Mycobacterial Disease Epidemiology: You Can See the Stars and Still Not See the Light. <i>Clinical Infectious Diseases</i> , 2021, 73, e327-e329.	5.8	2
52	The impact of different antibiotic treatment regimens on mortality in <i>Mycobacterium avium</i> complex pulmonary disease: a population-based cohort study. <i>European Respiratory Journal</i> , 2020, 56, 1901875.	6.7	2
53	<i>Aspergillus</i> isolation in nontuberculous mycobacterial pulmonary disease: Associated with antimycobacterial treatment initiation but not response. <i>Respiratory Medicine</i> , 2021, 179, 106338.	2.9	2
54	Treatment outcomes of nontuberculous mycobacterial pulmonary disease in lung transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13679.	1.7	1

#	ARTICLE	IF	CITATIONS
55	Sputum smear microscopy predicting mycobacterial culture in Ontario: A population-based laboratory report. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2019, 3, 39-42.	0.5	0
56	Clofazimine Drug Susceptibility Testing for Nontuberculous Mycobacteria. <i>Chest</i> , 2021, 160, e90.	0.8	0